COVID-19: Understanding What We Know After Five Years

Words From the Researchers (8/10)
“Most of the vaccinated individuals were between 20 and 59 years old, and France was the country where the highest number of doses were administered,” the researchers explained. The vaccines examined were produced by Pfizer, Moderna, and AstraZeneca.
These results added to the ongoing debates among healthcare professionals and patients alike.

Guillain-Barré Syndrome and Venous Thrombosis (9/10)
Researchers observed an increase in cases of Guillain-Barré syndrome (GBS) and cerebral venous thrombosis (CVT) following the first dose of the AstraZeneca vaccine.

Guillain-Barré syndrome typically causes progressive muscle weakness.

Cerebral venous thrombosis occurs when a blood clot forms in a vein in the brain, obstructing blood circulation.

French basketball player Victor Wembanyama previously suffered from a form of thrombosis, which forced him to end his season.

More Research Is Needed (10/10)
In addition, all vaccines showed an increased risk of myocarditis and pericarditis — inflammations of the heart muscle or its surrounding tissue — although these events remain rare.

Continue reading…